chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received Covid booster on 4/28/22. Patient had no problems until 5/9/22 when parent had to go pick patient up from school. Patient complained of having a bad pain starting from the top of his head and traveling down to his eyes causing him to lose vision in his left eye. Parent then took patient to the eye doctor. Doctor stated that patient may have been experiencing ocular migraine. Parent concerned because husband and child had the same symptoms days apart.
pain from left elbow to left shoulder with pain/deep ache all around the left shoulder, and Nausea. She states the nausea started just shortly after receiving the injection, and the pain started two hours after receiving the injection. She states she hates shots and gets nervous; however, the nausea continued until the next day. the injection site is hard, sore to touch with mild bruising noted. No redness or heat noted. However, this time the band-aid did produce a local rash (in the shape of the Band-aid) it's the same type of band-aids i've applied to her skin with previous vaccinations.
Red rash on the injection site; Rash got bigger and was pink in the center and bright red on the borders; baseball ball; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Red rash on the injection site), VACCINATION SITE ERYTHEMA (Rash got bigger and was pink in the center and bright red on the borders) and VACCINATION SITE SWELLING (baseball ball) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, the patient experienced VACCINATION SITE RASH (Red rash on the injection site), VACCINATION SITE ERYTHEMA (Rash got bigger and was pink in the center and bright red on the borders) and VACCINATION SITE SWELLING (baseball ball). At the time of the report, VACCINATION SITE RASH (Red rash on the injection site), VACCINATION SITE ERYTHEMA (Rash got bigger and was pink in the center and bright red on the borders) and VACCINATION SITE SWELLING (baseball ball) was resolving. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Other relevant concomitant medications included Blood pressure medication, Thyroids medication, Sleeping pill, Stomach medication and Intestine problems medication.  Treatment information included Ice on the injection site.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested
20 minutes after receiving MMR vaccine, Pt. called, reporting that she developed rash, swelling and itching at site of vaccine. She has these symptoms radiating from injection site, moving around her arm.
Approximately 7 minutes after the vaccination was given, my face became red and flushed and I experienced a sensation of heat in my body.  I recieved additional monitoring by staff and felt better approximately 20 minutes later
I just tested positive for Covid 19; I just tested positive for Covid 19; If there are none what do you do; This is a spontaneous report from a contactable consumer (patient) and forwarded as an Adverse Event and Medical Inquiry by the  team on 03Aug2021.  A 64-years-old patient of an unspecified gender received bnt162b2 (BNT162B2, Solution for injection), dose 2 via an unspecified route of administration on Feb2021 (Batch/Lot number was not reported) as DOSE 2, SINGLE for covid-19 immunisation. Medical history included bladder cancer (2 yr) survivor and patient's husband who was positive was asthmatic and HP. The patient's concomitant medications were not reported. It was reported that the patient had vaccine back in Jan Feb. Patient just tested positive for Covid 19. The (State) board of health recommended an antibody test in 3 wks. It was stated that If there were none what do they do. The outcome of the events was unknown.   Information about lot/batch has been requested.
Sat down after receiving booster. Started feeling faint about 10 minutes afterwards, lightheaded, cold sweats, blurred vision. Briefly fainted while sitting in chair. Came to shortly afterwards and felt fine. Noticed heart rate spike and drop around the time of fainting via Watch
Red raised skin at injection site area , painful to touch and move arm.  About 2 inches in diameter
Fever, 102 Nausea  Loss of appetite  Chills Headache  Muscle pain Body aches  Chest pain
C/O  dizziness became clammy, radial pulse thready and unable to count @ first vital signs monitored, given Epi 0.3 mg right thigh @ 9:52 AM, vital signs monitored, EMT called and transported to Hospital
3-6-13 started with wheezing. 3-7-13 got worse as day went on wheezing, weakness, paleness, fast heartbeat, difficulty breathing. Hospital stay started 3-7-13 with oxygen/warm vapor mist, ended 3-11-13. As of 3-14-13 still wheezing, periods of "grunt" breathing.
Menactra given 4/27/05 7:30AM. Pt awoke 4/28/05 c/o aching all over, spoke to pt's mother 1:30PM 4/28/05. States pt feels better.
It all started with bloating and gas like feeling in my stomach that I could not release. That led me to pain then lead me to the GI doctor. He did a brief exam in the office and gave me medication - Dicyclomine 20mg 1 tablet 3x daily before meals as needed. GI doctor also has me taking a probiotic Align He scheduled me for some testing as well. Also experiencing diarrhea, hasn't gone away yet. I've never experienced GI problems in the past. This was a pretty drastic change. This coming Saturday, I will be going for a stomach scan.
patient received the trumenba dose too early. Patient did not have any adverse events related to the vaccine.
Night sweats, extreme soreness at injection site, hot spells (last 3 days after injection).
Day of (MON) - soreness at injection site, achy in the evening. NIGHT OF - "Whole body Restlessness" - kept waking up having to move my body, like Restless Legs only including the torso. Day after (TUE) - soreness at injection site, 100 degree fever, fatigue. Spent most of the day in bed. 2nd day after (WED) - soreness at injection site, some fatigue. 3rd day after (THU) - mild fatigue  Never had the "Whole body Restlessness" again.
second dose when the patient was 14yo only; first dose Jan 14th 2015, second dose Nov 12th 2018; This case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a 14-year-old female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   Previously administered products included Menveo (received 1st dose on 14th January 2015 unknown batch number.).   On 12th November 2018, the patient received the 2nd dose of Menveo. On 12th November 2018, unknown after receiving Menveo, the patient experienced inappropriate age at vaccine administration and drug dose administration interval too short. On an unknown date, the outcome of the inappropriate age at vaccine administration and drug dose administration interval too short were unknown.   Additional Information: GSK Receipt Date: 07-JUL-2022 Reporter's Comment:  Reporter stated that the patient received second dose of Menveo at the age 14 years only. Now the patient was 18 years old and requested a booster vaccine for the college, but Doctor realized that the second dose was too early. The reporter consented to follow up by email. Additional supportive information: The 14 year old patient received 2nd dose of Menveo, earlier than recommended interval, which led to inappropriate age at vaccine administration and shortening of vaccination schedule.
9:45am following TST and Menactra administration pt became pale and pupils dilated.  I had pt talk to me while coworker brought a bottle of water.  Pt's words were slow and slurred.  She took about 2 sips of water and fainted.  I used ammonia inhalant to wake her up.  Once she came to she could tell me her name, dob, where she was, and what she was doing here.  I provided peanut butter crackers and water.  She declined juice.  Pt stated she had not eaten breakfast that morning and feels she got herself worked up prior to coming in for vaccines.  We contacted her mother on the phone, who came over to the office.  I informed mother of the incident and our documenting procedures.  Mother took the child home with her.  I received a call at 11:15am from mother, who stated that approx 10:55am as she was driving patient home, she closed her eyes, and mom thought she may have fainted again.  When patient "woke up" her speech was slurred and she complained of numbness/tingling in her Left hand, and "didn't feel right".  During the phone call, patient stated she was feeling better and denied any more numbness or tingling in the L hand.  I advised mom that if these symptoms continue, to take the child to see her doctor or to the ED.  Patient's mother called clinic on 7/17/19 to inform RN that patient vomited a couple of times in the afternoon, but as of the morning of 7/17/19 she was feeling much better with no further symptoms.
Initial report was received via a search of the scientific literature on 08 February 2012. Since 2002, approximately 40,000 civilians and 2.1 million other personnel have been vaccinated against smallpox. The vaccine contains live vaccinia virus that can be transferred through physical contact. This report summarized numbers, rates and characteristics of contact vaccinia cases that presented between December 2001 and March 2011. Cases were identified from reports in adverse event reporting systems and peer-reviewed literature. One hundred fifteen cases of vaccinia transmission through contact were identified (5.4 per 100, 000 vaccinees); 52 reports (45%) noted laboratory confirmation. Three-quarters of vaccinees, but fewer than 8% of contact vaccinia cases, were described as other. Most cases were household or intimate contacts (n = 86, 75 percent) or wrestling partners (n = 18, 16%) of vaccinees. Nearly all cases manifested mild local skin reactions; of 14 hospitalized cases, one was life-threatening. The authors further noted that of the 115 contact transfer cases, 104 were secondary and 7 were tertiary (source was unknown for four). Fifty three (46%) cases presented in 2003, 17 in 2004, and 5 to 9 in each subsequent year. Cases were residents of 29 states; 2 cases involved other overseas. There were 95 adults, 3 adolescents (16-17 years) and 17 children (average age: 4). Eighty-two percent (n = 78) of affected adults were 18-29 years old, and more than two-thirds (n = 67) of adult/adolescent cases were females. Eight (47%) affected children were greater than or equal to two years old. Twenty-six contact cases (23%) were identified as civilians or were under the minimum age for enlistment. Nine others(8%), all male, were infected after contact with other members. In nearly three quarters (n = 85) of the cases, the source was a other vaccinee. For the other 30 cases, the status of the source was not reported. Civilian cases with secondary vaccinia infections did not transmit the virus to tertiary cases (n = 5); however no report specified a civilian as the original source of infection. Most contact vaccinia cases were adult/adolescent women (n = 67) or children (n = 17) who lived in the same household and/or shared a bed with a vaccinee or a vaccinee's contact. Of adult/adolescent female cases, most (n = 57) were described as intimate partners or were wives of vaccinees or secondary contacts. The others were household members (n = 3), healthcare workers (n = 2), or of unknown relationship to the source (n = 2). All child cases were contacts of parents or caregivers who were either vaccinees or secondary cases. Outcomes were not reported. Documents held by sender: None.
nausea.  patient counseled to see PCP.    Pt. declined further eval by EMS and hospital transport.
Employee received the COVID 19 vaccine on 12/30/2020 in her left deltoid.  At time of vaccination left arm was sore, but no other issues.  In early January the employee noticed she could not lift the normal weights while doing overhead presses or working the left shoulder.  On 1/24/2021 she noticed she could not lift a half gallon jug of milk into the refrigerator with her left arm.  Employee states the shoulder is not painful when lifting, but she can't lift more than 5 lbs with her left arm because it "gets stuck" when the arm is parallel to the shoulder.  Left shoulder feels weak.  Left deltoid area is still tender to the touch, but not painful when moving it.   Employee denied bruising, lumps, or swelling in lef
17JUN93 pt recvd vax @ approx 8AM; pt phoned @ approx 330PM c/o drawing of face, also stated has hx of high blood pressure controlled by medication; advised to consult pvt MD;
Extreme diarrhea; extreme discomfort; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 91-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Sep2022 as dose 5 (booster), single (Lot number: GJ2524) at the age of 91 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, single, Lot Number: EL1233, No. of Previous Doses: 0), administration date: 19Jan2021, when the patient was 89-year-old, for Covid-19 immunization; BNT162b2 (Dose 2, single, Lot Number: EL9269, No. of Previous Doses: 1), administration date: 09Feb2021, when the patient was 89-year-old, for Covid-19 immunization; BNT162b2 (Dose 3 (Booster), single, No. of Previous Doses: 2), administration date: 20Aug2021, when the patient was 89-year-old, for Covid-19 immunization; BNT162b2 (Dose 4 (Booster), single, Lot Number: FK9729, No. of Previous Doses: 3), administration date: 21Feb2022, when the patient was 90-year-old, for Covid-19 immunization. The following information was reported: DIARRHOEA (non-serious) with onset 15Sep2022, outcome "recovered" (18Sep2022), described as "Extreme diarrhea"; DISCOMFORT (non-serious) with onset 15Sep2022, outcome "recovered" (18Sep2022), described as "extreme discomfort". Therapeutic measures were taken as a result of diarrhoea, discomfort. Additional information: Patient stated that, he took a pill of Diphenoxylate/Tropine that stopped the diarrhea, medication was effective and diarrhea started to stop after an hour or so. He was used Kaopectate first for the diarrhea, but didn't work. He was used over the counter product, states distributer as (Name withheld), but unknown manufacturer 2 tablespoons each dose. Patient stated, he was fine. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.   Follow-up attempts are completed. No further information is expected.
Fever, chills, body aches, joint aches, headache, earache, sore throat, fatigue
In hospital after 1st dose; 2nd dose delayed; This spontaneous case was reported by a consumer and describes the occurrence of HOSPITALISATION (In hospital after 1st dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HOSPITALISATION (In hospital after 1st dose) (seriousness criterion hospitalization) and PRODUCT DOSE OMISSION ISSUE (2nd dose delayed). At the time of the report, HOSPITALISATION (In hospital after 1st dose) and PRODUCT DOSE OMISSION ISSUE (2nd dose delayed) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.  Company Comment: Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.; Sender's Comments: Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Information has been received from an unspecified reporter via a Merck employee referring to a more than 65 year old male patient. The patient's concurrent condition, medical history and concomitant therapy were not provided. On an unknown date, the patient was vaccinated with a dose of PNEUMOVAX 23 (lot# reported as 2568254242 (invalid), dose, route, and expiration date were unknown) for prophylaxis. Another flu vaccine was also vaccinated in the same arm on the same day. On an unknown date, the patient's arm swelled up and he experienced a fever. The patient did not seek medical attention and had no treatment. The outcome of the events was recovered. Causality was not provided. Additional information has been requested.
Had varicella vaccine on 1/18/06, and on 2/6/06 was seen in my office for 3 days of fever, fatigue, myalgias;  then by the next day had a disseminated vesicular rash, which looked like a mild case of varicella.
Patient had a syncopal episode 20 minutes after vaccine was administered.  Was not arousable for 10 seconds.  He said he has not experienced this before.  Sent to Emergency Department for further observation.
At 5:00 am i feel shivering  and have fever   and my left arm hurt.  I take some tylenol to reduced my fever and it works. when i get up like 9:00 am  i vomit
Information has been received from a physician concerning two patients who on an unknown date was vaccinated with a dose of ROTATEQ.  On an unspecified date, post vaccination, the patients experienced diarrhea.  At the time of the report the patients statuses were unknown.  A product quality complaint was not involved.  Attempts made to obtain additional identifying information to distinguish the individual patients mentioned in this report were unsuccessful.  Additional information has been requested.
Approximately two weeks after each dose, I broke out in a full body rash.  I had an appointment with my dermatologist who prescribed Prednisone. This cleared up the rash, but as soon as the prescription was over, the rash came back. A topical cream was prescribed to use which is more safe. My dermatologist recommended I see an Allergist. I saw an allergist who tested me for several types of allergens. I have never in my 37 years of living had any type of allergy; food or environmental. Ultimately, the scratch test showed that I am now allergic to every single environmental allergen. This rash will not go away. It is the most uncomfortable full body rash that itches endlessly. There has been no outcome as of yet. I have been dealing with trying to manage this rash since mid March of 2021 after receiving the first Moderna dose.
Patient received the first three doses in 2018, but hasn't gotten the booster; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix with an associated reaction of no adverse event (received the first three doses in 2018).   On an unknown date, the patient received Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, patient did not received booster dose of Twinrix, which led to incomplete course of vaccination. The reporter asked if the patient need to repeat the entire series. The health care professional declined to leave any patient details and declined follow up. The reporter did not consent to follow-up.
Patient said she looked red - she didn't seem to be red.  She said her fingers felt a little swollen like they do when she eats bbq.  I had her stay 30 minutes longer for observation.  She was fine at that time.
Pregnancy and miscarriage.     Hx: one living child born 4/19/19. No hx of miscarriage. Attempted to get pregnant ~3 months post vaccination. Taking prenatal for 3 months prior to attempt to get pregnant.   Date of LMP was 3/29/2021. Found out I was pregnant was twins via vaginal US at 8 weeks. Normal growth, heartbeats present. Second OB appointment at 11 weeks 5 days. No heartbeat present with either child on US. One twin measured 9 wks 5 day, other twin measured 10 weeks. D&C completed 6/22/21. No complications.
A 52 year old patient experienced inadequate antibody levels after prophylactic treatment with RabAvert. The patient received RabAvert 10/03/02, 10/10/02 followed by a third injection 2 to 3 weeks later. On 05/01/04, enzyme linked immunosorbent assay (ELISA) testing was performed and showed inadequate antibody levels. On 06/15/04, rapid fluorescent focus inhibition test (RFFIT) was performed and showed below acceptable antibody levels. A Booster shot was suggested due to the low post vaccination titers. The reporter stated that a booster would be obtained and follow up titers reported. Follow up information received on 07/02/04: The correct lot number for the RabAvert is 309011, expiration date 10/2005. The RFFIT result for this patient was 0.3IU/ml. Follow up information received 08/04/04: the RFFIT test results was converted to dilution to compare to the ACIP recommendation of an adequate rabies virus neutralizing antibody titer (greater or equal to a serum dilution of 1:5 resulting in complete neutralization of rabies virus in RFFIT). The first RFFIT neutralizing antibody dilution results were 1:19. No retesting was necessary. According to the ACIP recommendations, the patient did not need a booster dose of vaccine.
arm soreness; fever; headache; fatigue; nausea; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness), PYREXIA (fever), HEADACHE (headache), FATIGUE (fatigue) and NAUSEA (nausea) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047A21A and 047A21A) for COVID-19 vaccination.     Concurrent medical conditions included Osteoporosis and Hypercholesterolemia. Concomitant products included ROSUVASTATIN for Hypercholesterolemia, CALCIUM CITRATE and DENOSUMAB (PROLIA) for Osteoporosis.   On 23-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 23-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm soreness), PYREXIA (fever), HEADACHE (headache), FATIGUE (fatigue) and NAUSEA (nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 25-Feb-2021, PAIN IN EXTREMITY (arm soreness), PYREXIA (fever), HEADACHE (headache), FATIGUE (fatigue) and NAUSEA (nausea) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       This case was linked to MOD-2021-059629 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 12-May-2021: Follow up received on 12-May-2021 and updated reporter contact information. On 12-Jul-2021: Follow up received on 12-Jul-2021 and contains no new information
Complaint of limited range of motion in arm where injection was given. L arm - started the day after injection.